Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing mechanism-based therapeutics for the treatment of obesity, has received a second broad patent from the US Patent and Trademark Office for its invention entitled inhibition of olfactory neurosensory function to treat obesity and related disorders.
Subscribe to our email newsletter
The patent broadly protects key aspects of Compellis’ novel obesity therapeutic strategy. CP404 is a calcium channel blocker used in a nasal formulation to block olfactory activity and reduce food intake. Compellis has tested a series of like compounds and the effect can be seen in the overall class of calcium channel blockers.
Based on its prior use in humans for certain other disorders, Compellis believes some of the drawbacks typically associated with unproven compounds will not be an issue with CP404. The advantage of CP404 is that because it is a small molecule, it is well-tolerated in man and is readily manufactured, the company said.
Chris Adams, president and CEO of Compellis Pharmaceuticals, said: “This second patent issuance significantly broadens the company’s intellectual property portfolio and is a valuable asset for its obesity therapeutic platform. This second patent expands the scope of the company’s invention by protecting a broad class of calcium channel antagonists to treat obesity.
“This includes all new and existing molecules, covering both methods and composition of matter. This second patent greatly enhances the commercial potential of Compellis’s obesity therapeutic strategy. The next step in development is completion of human testing with CP404.”